Robert F. Kennedy Jr.’s removal of all remaining members of the CDC’s Advisory Committee on Immunization Practices raises ...

Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to ...

Odyssey first filed for an IPO in January alongside fellow Massachusetts biotech Sionna Therapeutics. The latter company ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

The reinstatement of the generic drug policy office is the latest reversal of course for Robert F. Kennedy Jr.'s HHS, which ...

Two weeks of upheaval at the CDC culminated Monday in the complete reconstitution of the CDC’s Advisory Committee on ...

Avidity has been given the go-ahead by the FDA to request accelerated approval of delpacibart braxlosiran—potentially the ...

The loss of special government employee status for four members of the CDC’s Advisory Committee on Immunization Practices ...

After a major shareholder pushed back, Keros is returning half of its capital to investors in a move that Guggenheim analysts ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained ...